0.409

7.35% +0.028

Trevena Inc (TRVN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Trevena Inc stock is currently priced at $0.409, with a 24-hour trading volume of 114.79K. It has seen a +7.35% increased in the last 24 hours and a -5.98% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.3783 pivot point. If it approaches the $0.4188 resistance level, significant changes may occur.

Previous Close:

$0.381

Open:

$0.38

24h Volume:

114.79K

Market Cap:

$7.49M

Revenue:

$3.13M

Net Income/Loss:

$-40.29M

P/E Ratio:

-0.0913

EPS:

-4.48

Net Cash Flow:

$-33.08M

1W Performance:

+11.75%

1M Performance:

-5.98%

6M Performance:

-24.68%

1Y Performance:

-34.56%

1D Range:

$0.37

$0.4199

52W Range:

$0.3001

$3.28

Trevena Inc Stock (TRVN) Company Profile

Name

Trevena Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

610 354 8840

Address

955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

TRVN's Discussions on Twitter

Trevena Inc Stock (TRVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-15-21	Initiated	Oppenheimer	Perform
Sep-14-20	Initiated	Guggenheim	Buy
Aug-28-20	Initiated	Cantor Fitzgerald	Overweight
May-31-19	Resumed	H.C. Wainwright	Buy
Nov-05-18	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-12-18	Downgrade	Needham	Buy → Hold
Oct-10-18	Downgrade	Jefferies	Buy → Hold
Nov-08-17	Reiterated	Needham	Buy
Oct-16-17	Downgrade	Barclays	Overweight → Equal Weight
Oct-12-17	Reiterated	H.C. Wainwright	Buy
May-08-17	Reiterated	Needham	Buy
Feb-23-17	Reiterated	H.C. Wainwright	Buy
Feb-22-17	Reiterated	FBR & Co.	Outperform
Feb-02-17	Initiated	Ladenburg Thalmann	Buy
Jan-09-17	Initiated	H.C. Wainwright	Buy
Jan-05-17	Initiated	Oppenheimer	Outperform
May-17-16	Reiterated	FBR Capital	Outperform
May-17-16	Reiterated	Needham	Buy
Mar-29-16	Initiated	FBR Capital	Outperform
Sep-01-15	Reiterated	Wedbush	Outperform
Aug-03-15	Initiated	Brean Capital	Buy

View All

Trevena Inc Stock (TRVN) Latest News

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

GlobeNewswire Inc.

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

GlobeNewswire Inc.

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

GlobeNewswire Inc.

Trevena Awarded OLINVYK Agreement with Premier, Inc.

GlobeNewswire Inc.

Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Benzinga

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire Inc.

Trevena Inc Stock (TRVN) Financials Data

Trevena Inc (TRVN) Revenue 2024

TRVN reported a revenue (TTM) of $3.12 million for the quarter ending December 31, 2023, a -9.58% decline year-over-year.

Trevena Inc (TRVN) Net Income 2024

TRVN net income (TTM) was -$40.29 million for the quarter ending December 31, 2023, a +24.85% increase year-over-year.

Trevena Inc (TRVN) Cash Flow 2024

TRVN recorded a free cash flow (TTM) of -$33.08 million for the quarter ending December 31, 2023, a +35.78% increase year-over-year.

Trevena Inc (TRVN) Earnings per Share 2024

TRVN earnings per share (TTM) was -$3.20 for the quarter ending December 31, 2023, a +58.50% growth year-over-year.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.